| Report Code: 40211 | Published: January 2019 | Pages: 142 | Available format: |
| Therapeutic Area(s): | Nephrology | Report Type: Competitive Landscape Reports |
Chapter 1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.3.1 Pipeline Analysis by Phase
1.3.2 Pipeline Analysis by Molecule Type
1.3.3 Pipeline Analysis by Route of Administration
1.4 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.1.1 Secondary Sources for Epidemiology Analysis
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents
2.2.1.1 By industry participant
2.2.1.2 By company type
2.2.2 KOLs Validation
2.3 Coverage of Epidemiology Analysis
2.4 Forecast Methodology for Epidemiology Analysis
2.5 Assumptions for Epidemiology Analysis
Chapter 3. Executive Summary
Chapter 4. Pipeline Outlook
4.1 Disease Overview
4.2 Causes
4.3 Signs and Symptoms
4.4 Pathophysiology
4.5 Diagnosis
4.6 Treatment
4.7 Key Drivers
4.7.1 Lack of Availability of Specific Treatment
4.7.2 Development of Various Promising Targets
4.8 Key Barrier
4.8.1 No Early Signs or Symptoms
4.9 IgA Nephropathy Therapeutics Pipeline Analysis
4.9.1 Pipeline Analysis by Phase
4.9.2 Pipeline Analysis by Molecule Type
4.9.3 Pipeline Analysis by Route of Administration
4.9.4 Pipeline Analysis by Company
Chapter 5. IgA Nephropathy Epidemiology Overview
5.1 IgA Nephropathy Epidemiology Forecast for 7MM
5.1.1 IgA Nephropathy Epidemiology Forecast for the U.S.
5.1.2 IgA Nephropathy Epidemiology Forecast for Japan
5.1.3 IgA Nephropathy Epidemiology Forecast for EU5
5.1.3.1 IgA nephropathy epidemiology for the U.K.
5.1.3.2 IgA nephropathy epidemiology for Germany
5.1.3.3 IgA nephropathy epidemiology for France
5.1.3.4 IgA nephropathy epidemiology for Italy
5.1.3.5 IgA nephropathy epidemiology for Spain
Chapter 6. IgA Nephropathy Conferences (2018)
6.1 Recently Organized/Held Seminars and Conferences
6.2 Upcoming Seminar and Conferences
Chapter 7. IgA Nephropathy Therapeutics Pipeline Analysis by Phase (2018) 60
7.1 Phase III
7.1.1 ACTH (Acthar) Gel
7.1.1.1 Clinical trials
7.1.1.2 Clinical results
7.1.1.3 Strategic development
7.1.2 XXXX
7.1.2.1 Clinical trials
7.1.2.2 Clinical results
7.1.2.3 Strategic development
7.1.2.4 Designation
7.1.2.5 Patent
7.1.2.6 Financing
7.1.2.7 Technology
7.1.3 XXXX
7.1.3.1 Clinical trials
7.1.3.2 Clinical results
7.1.3.3 Strategic development
7.1.3.4 Designation
7.1.4 XXXX
7.1.4.1 Clinical trials
7.1.4.2 Strategic development
7.2 Phase II/III
7.2.1 Blisibimod
7.2.1.1 Clinical trials
7.2.1.2 Clinical results
7.2.1.3 Strategic development
7.3 Phase II
7.3.1 Atacicept
7.3.1.1 Clinical trials
7.3.2 XXXX
7.3.2.1 Clinical trials
7.3.2.2 Clinical results
7.3.3 XXXX
7.3.3.1 Clinical trials
7.3.4 XXXX
7.3.4.1 Clinical trials
7.3.5 XXXX
7.3.5.1 Clinical trials
7.3.6 XXXX
7.3.6.1 Clinical trials
7.3.6.2 Clinical trial results
7.3.6.3 Strategic development
7.4 Phase I
7.4.1 VIS649
7.4.1.1 Pre-Clinical study
7.4.1.2 Clinical trials
7.4.1.3 Strategic development
7.4.1.4 Technology
7.5 Pre-Clinical
7.5.1 IgA Protease
7.5.1.1 Grant
7.5.2 XXXX
7.5.3 XXXX
7.6 Unknown
7.6.1 IL-6 antibody
7.6.1.1 Patent
7.6.2 XXXX
7.7 Discovery
7.7.1 Drug Candidate for IgA Nephropathy - Polyneuron Pharmaceuticals AG
7.8 Inactive
7.8.1 Ramipril
7.8.1.1 Clinical trials
7.8.1.2 Strategic development
7.8.2 XXXX
7.8.2.1 Clinical trials
7.8.3 XXXX
7.8.3.1 Clinical trials
7.8.4 XXXX
7.8.4.1 Clinical trials
7.9 Discontinued
7.9.1 SM101
7.9.1.1 Clinical trials
7.9.2 XXXX
Chapter 8. Clinical Trials Review
8.1 Clinical Trials by Region
8.2 Clinical Trials by Trial Status
Chapter 9. Competitive Landscape
9.1 Key Player Benchmarking
9.2 SWOT Analysis of IgA Nephropathy Pipeline
Chapter 10. Company Profiles
10.1 Mallinckrodt plc
10.1.1 Business Overview
10.1.2 Product Offerings
10.2 Visterra Inc.
10.2.1 Business Overview
10.2.2 Product Offerings
10.3 XXXX.
10.3.1 Business Overview
10.3.2 Product Offerings
10.4 XXXX
10.4.1 Business Overview
10.4.2 Product Offerings
10.5 XXXX
10.5.1 Business Overview
10.5.2 Product Offerings
10.6 Omeros Corporation
10.6.1 Business Overview
10.6.2 Product Offerings
10.7 XXXX
10.7.1 Business Overview
10.7.2 Product Offerings
10.8 IGAN Biosciences Inc.
10.8.1 Business Overview
10.8.2 Product Offerings
Chapter 11. Appendix
11.1 Abbreviation
11.2 Related Reports
LIST OF TABLES
TABLE 1 PIPELINE ANALYSIS OF IGA NEPHROPATHY THERAPEUTICS, BY COMPANY (2018)
TABLE 2 IGA NEPHROPATHY EPIDEMIOLOGY FOR 7MM (2016-2021)
TABLE 3 IGA NEPHROPATHY EPIDEMIOLOGY FOR 7MM (2022-2028)
TABLE 4 IGA NEPHROPATHY EPIDEMIOLOGY FOR THE U.S. (2016-2021)
TABLE 5 IGA NEPHROPATHY EPIDEMIOLOGY FOR THE U.S. (2022-2028)
TABLE 6 IGA NEPHROPATHY EPIDEMIOLOGY FOR JAPAN (2016-2021)
TABLE 7 IGA NEPHROPATHY EPIDEMIOLOGY FOR JAPAN (2022-2028)
TABLE 8 IGA NEPHROPATHY EPIDEMIOLOGY FOR EU5 (2016-2021)
TABLE 9 IGA NEPHROPATHY EPIDEMIOLOGY FOR EU5 (2022-2028)
TABLE 10 IGA NEPHROPATHY EPIDEMIOLOGY FOR THE U.K. (2016-2021)
TABLE 11 IGA NEPHROPATHY EPIDEMIOLOGY FOR THE U.K. (2022-2028)
TABLE 12 IGA NEPHROPATHY EPIDEMIOLOGY FOR GERMANY (2016-2021)
TABLE 13 IGA NEPHROPATHY EPIDEMIOLOGY FOR GERMANY (2022-2028)
TABLE 14 IGA NEPHROPATHY EPIDEMIOLOGY FOR FRANCE (2016-2021)
TABLE 15 IGA NEPHROPATHY EPIDEMIOLOGY FOR FRANCE (2022-2028)
TABLE 16 IGA NEPHROPATHY EPIDEMIOLOGY FOR ITALY (2016-2021)
TABLE 17 IGA NEPHROPATHY EPIDEMIOLOGY FOR ITALY (2022-2028)
TABLE 18 IGA NEPHROPATHY EPIDEMIOLOGY FOR SPAIN (2016-2021)
TABLE 19 IGA NEPHROPATHY EPIDEMIOLOGY FOR SPAIN (2022-2028)
TABLE 20 KEY IGA NEPHROPATHY CONFERENCES HELD IN 2018
TABLE 21 UPCOMING IGA NEPHROPATHY SEMINAR AND CONFERENCES
TABLE 22 DESCRIPTION OF ACTH (ACTHAR) GEL
TABLE 23 CLINICAL TRIALS OF ACTH (ACTHAR) GEL
TABLE 24 DESCRIPTION OF NEFECON
TABLE 25 CLINICAL TRIALS OF NEFECON
TABLE 26 DESCRIPTION OF XXXX
TABLE 27 CLINICAL TRIALS OF XXXX
TABLE 28 DESCRIPTION OF XXXX
TABLE 29 CLINICAL TRIALS OF XXXX
TABLE 30 DESCRIPTION OF BLISIBIMOD
TABLE 31 CLINICAL TRIALS OF BLISIBIMOD
TABLE 32 DESCRIPTION OF ATACICEPT
TABLE 33 CLINICAL TRIALS OF ATACICEPT
TABLE 34 DESCRIPTION OF XXXX
TABLE 35 CLINICAL TRIALS OF XXXX
TABLE 36 CLINICAL TRIALS PHASE II RESULTS OF XXXX
TABLE 37 DESCRIPTION OF XXXX
TABLE 38 CLINICAL TRIALS OF XXXX
TABLE 39 DESCRIPTION OF XXXX
TABLE 40 DESCRIPTION OF XXXX
TABLE 41 CLINICAL TRIALS OF XXXX
TABLE 42 DESCRIPTION OF XXXX
TABLE 43 CLINICAL TRIALS OF XXXX
TABLE 44 DESCRIPTION OF VIS649
TABLE 45 CLINICAL TRIALS OF VIS649
TABLE 46 DESCRIPTION OF IGA PROTEASE
TABLE 47 DESCRIPTION OF XXXX
TABLE 48 DESCRIPTION OF XXXX
TABLE 49 DESCRIPTION OF IL-6 ANTIBODY
TABLE 50 DESCRIPTION OF XXXX
TABLE 51 DESCRIPTION OF DRUG CANDIDATE FOR IGA NEPHROPATHY - POLYNEURON PHARMACEUTICALS AG
TABLE 52 DESCRIPTION OF RAMIPRIL
TABLE 53 CLINICAL TRIALS OF RAMIPRIL
TABLE 54 DESCRIPTION OF XXXX
TABLE 55 CLINICAL TRIALS OF XXXX
TABLE 56 DESCRIPTION OF XXXX
TABLE 57 CLINICAL TRIALS OF XXXX
TABLE 58 DESCRIPTION OF XXXX
TABLE 59 CLINICAL TRIALS OF XXXX
TABLE 60 DESCRIPTION OF SM101
TABLE 61 CLINICAL TRIALS OF SM101
TABLE 62 DESCRIPTION OF XXXX
TABLE 63 CLINICAL TRIALS OF XXXX
TABLE 64 MALLINCKRODT PLC – AT A GLANCE
TABLE 65 XXXX – AT A GLANCE
TABLE 66 XXXX – AT A GLANCE
TABLE 67 XXXX – AT A GLANCE
TABLE 68 XXXX – AT A GLANCE
TABLE 69 OMEROS CORPORATION – AT A GLANCE
TABLE 70 XXXX – AT A GLANCE
TABLE 71 XXXX. – AT A GLANCE
LIST OF FIGURES
FIG 1 RESEARCH METHODOLOGY
FIG 2 BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT
FIG 3 BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY COMPANY TYPE
FIG 4 PATHOPHYSIOLOGY OF IGA NEPHROPATHY
FIG 5 TREATMENT ALGORITHM OF IGA NEPHROPATHY
FIG 6 IGA NEPHROPATHY DRUG CANDIDATES UNDER DEVELOPMENT (2018)
FIG 7 IGA NEPHROPATHY PIPELINE SPLIT, BY MOLECULE TYPE (2018)
FIG 8 IGA NEPHROPATHY PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2018)
FIG 9 TOTAL NUMBER OF PREVALENT CASES FOR 7MM (2016 & 2028)
FIG 10 IGA NEPHROPATHY PREVALENCE RATE IN 7MM (2016-2028)
FIG 11 IGA NEPHROPATHY EPIDEMIOLOGY FOR 7MM (2016-2028)
FIG 12 IGA NEPHROPATHY EPIDEMIOLOGY FOR THE U.S. (2016-2028)
FIG 13 IGA NEPHROPATHY EPIDEMIOLOGY FOR JAPAN (2016-2028)
FIG 14 IGA NEPHROPATHY EPIDEMIOLOGY FOR EU5 (2016-2028)
FIG 15 IGA NEPHROPATHY EPIDEMIOLOGY FOR THE U.K. (2016-2028)
FIG 16 IGA NEPHROPATHY EPIDEMIOLOGY FOR GERMANY (2016-2028)
FIG 17 IGA NEPHROPATHY EPIDEMIOLOGY FOR FRANCE (2016-2028)
FIG 18 IGA NEPHROPATHY EPIDEMIOLOGY FOR ITALY (2016-2028)
FIG 19 IGA NEPHROPATHY EPIDEMIOLOGY FOR SPAIN (2016-2028)
FIG 20 PHASE II RESULTS OF OMS721 IN IGA NEPHROPATHY: 24-HR URINE PROTEIN (1)
FIG 21 PHASE II RESULTS OF OMS721 IN IGA NEPHROPATHY: 24-HR URINE PROTEIN (2)
FIG 22 PHASE II AND FOLLOW-UP RESULTS – IGA NEPHROPATHY: EGFR
FIG 23 BREAKDOWN OF CLINICAL TRIALS, BY REGION
FIG 24 BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS
FIG 25 KEY PLAYER BENCHMARKING
FIG 26 SWOT ANALYSIS OF IGA NEPHROPATHY PIPELINE